Phospho-SIRT1 (Ser47) Antibody (Rabbit mAb) [P1D17]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 - 1:2000 IHC1:250 - 1:500 IF1:100 - 1:250

Application
WB, IHC, IF

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
82 kDa 82 kDa, 110 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Phospho-SIRT1 (Ser47) Antibody (Rabbit mAb) [P1D17] detects endogenous levels of total SIRT1 protein only when it is phosphorylated at Ser47.

Clone
P1D17

Synonym(s)
SIR2L1, SIRT1, NAD-dependent protein deacetylase sirtuin-1, hSIRT1, NAD-dependent protein deacylase sirtuin-1, Regulatory protein SIR2 homolog 1, SIR2-like protein 1, Hsir2

Background
Phospho‑SIRT1 (Ser47) designates a regulatory state of the class I sirtuin deacetylase SIRT1 in which an N‑terminal serine is phosphorylated, adding an additional layer of control to a NAD‑dependent enzyme that coordinates transcriptional responses to metabolic, stress and inflammatory cues. SIRT1 contains a conserved central catalytic core flanked by extended N‑ and C‑terminal regions that mediate interactions with chromatin, transcription factors and signaling proteins; Ser47 lies in the N‑terminal segment, close to residues that regulate nuclear localization and binding to partners such as PML, and phosphorylation at this site defines a distinct phospho‑isoform recognized by multiple antibodies that detect SIRT1 only when modified at Ser47. Across tissues, SIRT1 deacetylates histones and non-histone substrates including p53, p300, Ku70, FOXO transcription factors, PPARγ and PGC‑1α, thereby repressing apoptosis, modulating stress resistance and reprogramming gluconeogenic and lipolytic pathways in response to nutrient status; Ser47 phosphorylation occurs in vivo along with Ser27, and kinase studies indicate that AMP‑activated protein kinase and other stress kinases can phosphorylate SIRT1 at N‑terminal serines to adjust its stability and activity in response to energy signals. Ser47 phosphorylation tracks SIRT1 involvement in positive regulation of insulin secretion in pancreatic β‑cells, where phospho‑S47 SIRT1 associates with repression of specific β‑cell genes and promotes glucose-stimulated insulin release, linking this phospho‑state to endocrine signaling and glucose homeostasis. Phospho‑Ser47 also marks SIRT1 populations engaged in chromatin-focused repression: Ser47‑phosphorylated SIRT1 deacetylates histones and influences histone and DNA methylation to enforce transcriptional silencing at target loci, integrating kinase signaling with epigenetic remodeling in pathways involving cell cycle control, DNA damage response, metabolism and autophagy. SIRT1 phosphorylated at N‑terminal sites including Ser47, resides in nuclear compartments such as PML bodies, euchromatin and heterochromatin and can shuttle to the cytoplasm, placing this phospho‑form at hubs where it can interact with APEX1 and other DNA repair and redox regulators, consistent with a role in genotoxic stress resistance. Persistent activation of stress kinases such as JNK1 promotes SIRT1 N‑terminal phosphorylation followed by ubiquitin‑mediated degradation, contributing to reduced SIRT1 levels and hepatic steatosis in obesity, so changes in Ser47 phosphorylation are part of a broader pattern in which N‑terminal phospho‑marks modulate SIRT1 turnover and thereby impact metabolic disease. In cardiovascular contexts, SIRT1 signaling is protective against vascular aging and heart disease through deacetylation of p65 NF‑κB, eNOS and other targets, and phospho‑SIRT1 detection (including Ser47) is used as a readout of SIRT1 engagement in these anti-inflammatory and vasoprotective pathways. The N‑terminal positioning of Ser47, in vivo phosphorylation, association with β‑cell insulin regulation, chromatin-centered transcriptional repression, stress-kinase–driven degradation, and clinical use as a marker of SIRT1 activity define phospho‑SIRT1 (Ser47) as a useful target state for dissecting how upstream kinases couple energy, stress and inflammatory signals to sirtuin-mediated deacetylation programs in metabolism, aging, cardiovascular disease and related immune pathologies.

Background

Phospho‑SIRT1 (Ser47) designates a regulatory state of the class I sirtuin deacetylase SIRT1 in which an N‑terminal serine is phosphorylated, adding an additional layer of control to a NAD‑dependent enzyme that coordinates transcriptional responses to metabolic, stress and inflammatory cues. SIRT1 contains a conserved central catalytic core flanked by extended N‑ and C‑terminal regions that mediate interactions with chromatin, transcription factors and signaling proteins; Ser47 lies in the N‑terminal segment, close to residues that regulate nuclear localization and binding to partners such as PML, and phosphorylation at this site defines a distinct phospho‑isoform recognized by multiple antibodies that detect SIRT1 only when modified at Ser47. Across tissues, SIRT1 deacetylates histones and non-histone substrates including p53, p300, Ku70, FOXO transcription factors, PPARγ and PGC‑1α, thereby repressing apoptosis, modulating stress resistance and reprogramming gluconeogenic and lipolytic pathways in response to nutrient status; Ser47 phosphorylation occurs in vivo along with Ser27, and kinase studies indicate that AMP‑activated protein kinase and other stress kinases can phosphorylate SIRT1 at N‑terminal serines to adjust its stability and activity in response to energy signals. Ser47 phosphorylation tracks SIRT1 involvement in positive regulation of insulin secretion in pancreatic β‑cells, where phospho‑S47 SIRT1 associates with repression of specific β‑cell genes and promotes glucose-stimulated insulin release, linking this phospho‑state to endocrine signaling and glucose homeostasis. Phospho‑Ser47 also marks SIRT1 populations engaged in chromatin-focused repression: Ser47‑phosphorylated SIRT1 deacetylates histones and influences histone and DNA methylation to enforce transcriptional silencing at target loci, integrating kinase signaling with epigenetic remodeling in pathways involving cell cycle control, DNA damage response, metabolism and autophagy. SIRT1 phosphorylated at N‑terminal sites including Ser47, resides in nuclear compartments such as PML bodies, euchromatin and heterochromatin and can shuttle to the cytoplasm, placing this phospho‑form at hubs where it can interact with APEX1 and other DNA repair and redox regulators, consistent with a role in genotoxic stress resistance. Persistent activation of stress kinases such as JNK1 promotes SIRT1 N‑terminal phosphorylation followed by ubiquitin‑mediated degradation, contributing to reduced SIRT1 levels and hepatic steatosis in obesity, so changes in Ser47 phosphorylation are part of a broader pattern in which N‑terminal phospho‑marks modulate SIRT1 turnover and thereby impact metabolic disease. In cardiovascular contexts, SIRT1 signaling is protective against vascular aging and heart disease through deacetylation of p65 NF‑κB, eNOS and other targets, and phospho‑SIRT1 detection (including Ser47) is used as a readout of SIRT1 engagement in these anti-inflammatory and vasoprotective pathways. The N‑terminal positioning of Ser47, in vivo phosphorylation, association with β‑cell insulin regulation, chromatin-centered transcriptional repression, stress-kinase–driven degradation, and clinical use as a marker of SIRT1 activity define phospho‑SIRT1 (Ser47) as a useful target state for dissecting how upstream kinases couple energy, stress and inflammatory signals to sirtuin-mediated deacetylation programs in metabolism, aging, cardiovascular disease and related immune pathologies.

References
https://pubmed.ncbi.nlm.nih.gov/25785061/ https://pubmed.ncbi.nlm.nih.gov/24959379/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%